Makoto Tahara
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.
Harrington K, Burtness B, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Brana I, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak W, Lin J, Gumuscu B, Swaby R, Rischin D. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. J Clin Oncol 2022:JCO2102508.
11.10.2022Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.
11.10.2022J Clin Oncol 2022:JCO2102508
Harrington Kevin J, Burtness Barbara, Greil Richard, Soulières Denis, Tahara Makoto, de Castro Gilberto, Psyrri Amanda, Brana Irene, Basté Neus, Neupane Prakash, Bratland Åse, Fuereder Thorsten, Hughes Brett G M, Mesia Ricard, Ngamphaiboon Nuttapong, Rordorf Tamara, Wan Ishak Wan Zamaniah, Lin Jianxin, Gumuscu Burak, Swaby Ramona F, Rischin Danny
Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis.
Müller-Jensen L, Zierold S, Versluis J, Boehmerle W, Huehnchen P, Endres M, Mohr R, Compter A, Blank C, Hagenacker T, Meier F, Reinhardt L, Gesierich A, Salzmann M, Hassel J, Ugurel S, Zimmer L, Banks P, Spain L, Soon J, Enokida T, Tahara M, Kähler K, Seggewiss-Bernhardt R, Harvey C, Long G, Schöberl F, von Baumgarten L, Hundsberger T, Schlaak M, French L, Knauss S, Heinzerling L. Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis. Data Brief 2022; 45:108649.
30.09.2022Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis.
30.09.2022Data Brief 2022; 45:108649
Müller-Jensen Leonie, Zierold Sarah, Versluis Judith M, Boehmerle Wolfgang, Huehnchen Petra, Endres Matthias, Mohr Raphael, Compter Annette, Blank Christian U, Hagenacker Tim, Meier Friedegund, Reinhardt Lydia, Gesierich Anja, Salzmann Martin, Hassel Jessica C, Ugurel Selma, Zimmer Lisa, Banks Patricia, Spain Lavinia, Soon Jennifer A, Enokida Tomohiro, Tahara Makoto, Kähler Katharina C, Seggewiss-Bernhardt Ruth, Harvey Catriona, Long Georgina V, Schöberl Florian, von Baumgarten Louisa, Hundsberger Thomas, Schlaak Max, French Lars E, Knauss Samuel, Heinzerling Lucie M
Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study.
Müller-Jensen L, Zierold S, Versluis J, Boehmerle W, Huehnchen P, Endres M, Mohr R, Compter A, Blank C, Hagenacker T, Meier F, Reinhardt L, Gesierich A, Salzmann M, Hassel J, Ugurel S, Zimmer L, Banks P, Spain L, Soon J, Enokida T, Tahara M, Kähler K, Seggewiss-Bernhardt R, Harvey C, Long G, Schöberl F, von Baumgarten L, Hundsberger T, Schlaak M, French L, Knauss S, Heinzerling L. Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study. Eur J Cancer 2022; 175:224-235.
22.09.2022Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study.
22.09.2022Eur J Cancer 2022; 175:224-235
Müller-Jensen Leonie, Zierold Sarah, Versluis Judith M, Boehmerle Wolfgang, Huehnchen Petra, Endres Matthias, Mohr Raphael, Compter Annette, Blank Christian U, Hagenacker Tim, Meier Friedegund, Reinhardt Lydia, Gesierich Anja, Salzmann Martin, Hassel Jessica C, Ugurel Selma, Zimmer Lisa, Banks Patricia, Spain Lavinia, Soon Jennifer A, Enokida Tomohiro, Tahara Makoto, Kähler Katharina C, Seggewiss-Bernhardt Ruth, Harvey Catriona, Long Georgina V, Schöberl Florian, von Baumgarten Louisa, Hundsberger Thomas, Schlaak Max, French Lars E, Knauss Samuel, Heinzerling Lucie M
Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.
Rischin D, Harrington K, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Brana I, Neupane P, Bratland Å, Fuereder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Ishak W, Hong R, Mendoza R, Jia L, Chirovsky D, Norquist J, Jin F, Burtness B. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. Oral Oncol 2022; 128:105815.
02.04.2022Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.
02.04.2022Oral Oncol 2022; 128:105815
Rischin Danny, Harrington Kevin J, Greil Richard, Soulières Denis, Tahara Makoto, de Castro Gilberto, Psyrri Amanda, Brana Irene, Neupane Prakash, Bratland Åse, Fuereder Thorsten, Hughes Brett G M, Mesia Ricard, Ngamphaiboon Nuttapong, Rordorf Tamara, Ishak Wan Zamaniah Wan, Hong Ruey-Long, Mendoza René Gonzalez, Jia Liyi, Chirovsky Diana, Norquist Josephine, Jin Fan, Burtness Barbara
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score.
Burtness B, Rischin D, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Brana I, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak W, Ge J, Swaby R, Gumuscu B, Harrington K. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. J Clin Oncol 2022; 40:2321-2332.
25.03.2022Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score.
25.03.2022J Clin Oncol 2022; 40:2321-2332
Burtness Barbara, Rischin Danny, Greil Richard, Soulières Denis, Tahara Makoto, de Castro Gilberto, Psyrri Amanda, Brana Irene, Basté Neus, Neupane Prakash, Bratland Åse, Fuereder Thorsten, Hughes Brett G M, Mesia Ricard, Ngamphaiboon Nuttapong, Rordorf Tamara, Wan Ishak Wan Zamaniah, Ge Joy, Swaby Ramona F, Gumuscu Burak, Harrington Kevin J
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
Gillison M, Blumenschein G, Fayette J, Guigay J, Colevas A, Licitra L, Harrington K, Kasper S, Vokes E, Even C, Worden F, Saba N, Iglesias Docampo L, Haddad R, Rordorf T, Kiyota N, Tahara M, Jayaprakash V, Weibel L, Ferris R. Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141. Oncologist 2022; 27:e194-e198.
04.03.2022Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
04.03.2022Oncologist 2022; 27:e194-e198
Gillison Maura L, Blumenschein George, Fayette Jerome, Guigay Joel, Colevas A Dimitrios, Licitra Lisa, Harrington Kevin J, Kasper Stefan, Vokes Everett, Even Caroline, Worden Francis, Saba Nabil F, Iglesias Docampo Lara Carmen, Haddad Robert, Rordorf Tamara, Kiyota Naomi, Tahara Makoto, Jayaprakash Vijayvel, Weibel Lisa, Ferris Robert L
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B, Harrington K, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak W, Hong R, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng J, Jin F, Rischin D. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019; 394:1915-1928.
01.11.2019Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
01.11.2019Lancet 2019; 394:1915-1928
Burtness Barbara, Harrington Kevin J, Greil Richard, Soulières Denis, Tahara Makoto, de Castro Gilberto, Psyrri Amanda, Basté Neus, Neupane Prakash, Bratland Åse, Fuereder Thorsten, Hughes Brett G M, Mesia Ricard, Ngamphaiboon Nuttapong, Rordorf Tamara, Wan Ishak Wan Zamaniah, Hong Ruey-Long, González Mendoza René, Roy Ananya, Zhang Yayan, Gumuscu Burak, Cheng Jonathan D, Jin Fan, Rischin Danny
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.
Gillison M, Blumenschein G, Fayette J, Guigay J, Colevas A, Licitra L, Harrington K, Kasper S, Vokes E, Even C, Worden F, Saba N, Iglesias Docampo L, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Li L, Ferris R. CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. Oncologist 2018; 23:1079-1082.
04.06.2018CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.
04.06.2018Oncologist 2018; 23:1079-1082
Gillison Maura L, Blumenschein George, Fayette Jerome, Guigay Joel, Colevas A Dimitrios, Licitra Lisa, Harrington Kevin J, Kasper Stefan, Vokes Everett, Even Caroline, Worden Francis, Saba Nabil F, Iglesias Docampo Lara Carmen, Haddad Robert, Rordorf Tamara, Kiyota Naomi, Tahara Makoto, Monga Manish, Lynch Mark, Li Li, Ferris Robert L
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
Ferris R, Blumenschein G, Fayette J, Guigay J, Colevas A, Licitra L, Harrington K, Kasper S, Vokes E, Even C, Worden F, Saba N, Docampo L, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison M. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol 2018; 81:45-51.
17.04.2018Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
17.04.2018Oral Oncol 2018; 81:45-51
Ferris Robert L, Blumenschein George, Fayette Jerome, Guigay Joel, Colevas A Dimitrios, Licitra Lisa, Harrington Kevin J, Kasper Stefan, Vokes Everett, Even Caroline, Worden Francis, Saba Nabil F, Docampo Lara Carmen Iglesias, Haddad Robert, Rordorf Tamara, Kiyota Naomi, Tahara Makoto, Lynch Mark, Jayaprakash Vijayvel, Li Li, Gillison Maura L
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
Ferris R, Blumenschein G, Fayette J, Guigay J, Colevas A, Licitra L, Harrington K, Kasper S, Vokes E, Even C, Worden F, Saba N, Iglesias Docampo L, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese W, Kopit J, Shaw J, Gillison M. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2016; 375:1856-1867.
08.10.2016Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
08.10.2016N Engl J Med 2016; 375:1856-1867
Ferris Robert L, Blumenschein George, Fayette Jerome, Guigay Joel, Colevas A Dimitrios, Licitra Lisa, Harrington Kevin J, Kasper Stefan, Vokes Everett, Even Caroline, Worden Francis, Saba Nabil F, Iglesias Docampo Lara Carmen, Haddad Robert, Rordorf Tamara, Kiyota Naomi, Tahara Makoto, Monga Manish, Lynch Mark, Geese William J, Kopit Justin, Shaw James W, Gillison Maura L